News | Prostate Cancer | July 02, 2024

The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care

The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer.”

In this new editorial, researchers Richard L.J. Qiu, Chih-Wei Chang, and Xiaofeng Yang from Emory University discuss prostate cancer. Prostate cancer persists as the most frequently diagnosed malignancy in men beyond skin cancer. Despite substantial advancements in treatment outcomes over the past half century, progression or recurrence post-initial treatments like prostatectomy or radiation therapy remains a challenge for a subset of patients. 

“In those scenarios, salvage radiation therapy is often offered to patients as a treatment option. To design the salvage radiation therapy, imaging is required to detect and locate the recurrence disease regime.” 

Traditional imaging modalities employed post-prostatectomy, such as CT, bone scans, MRI or 18F-FDG PET, often fall short in accurately detecting and determining the volume of the recurrent disease, which is crucial for salvage radiation treatment planning. However, the introduction of 18F-fluciclovine (anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) PET/CT has marked a significant advancement in salvage disease management. Recent studies, including the phase 2/3 randomized controlled trial, Emory Molecular Prostate Imaging for Radiotherapy Enhancement (EMPIRE-1), demonstrated improved biochemical recurrence or persistence free survival rates when incorporating 18F-fluciclovine PET/CT into post-prostatectomy radiation therapy planning.

One key step in salvage radiation therapy planning is the delineation of lesions on the 18F-fluciclovine PET/CT images, a task currently undertaken manually by physicians. This practice, while meticulous, is labor-intensive and prone to inter- and intra-observer variations. With the recent explosion of using artificial intelligence (AI) algorithms in medical image processing, automatic segmentation of lesions using deep learning (DL)-based lesion delineation methods demonstrate promising potential to improve treatment quality, as opposed to manual contouring. 

For more information: https://www.oncoscience.us/


Related Content

Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | Computed Tomography (CT)

Sept. 26, 2025 — At the American Society for Radiation Oncology (ASTRO) 2025 annual meeting in San Francisco, Calif ...

Time September 29, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Computed Tomography (CT)

Aug. 26, 2025— Esaote North America, Inc., a provider of dedicated MRI, Ultrasound, and Healthcare IT solutions, has ...

Time August 27, 2025
arrow
News | Prostate Cancer

Aug. 13, 2025 — A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer ...

Time August 15, 2025
arrow
News | RSNA

Aug. 13, 2025 — Registration is now open for the RSNA 111th Scientific Assembly and Annual Meeting, the world’s leading ...

Time August 13, 2025
arrow
News | Radiology Imaging

Aug. 12, 2025 – Medical imaging methods such as ultrasound and MRI are often affected by background noise, which can ...

Time August 12, 2025
arrow
News | Mammography

Aug. 5, 2025 — New Lantern has announced the launch of two specialized viewer modes: the Mammography Viewer Mode and PET ...

Time August 05, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
Subscribe Now